Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Mankind Pharma

Pharmaceutical intelligence for Mankind Pharma with 14 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
10
Catalysts
4
Assets
8

Recent signals(10)

RegulatoryAugust 6, 2026

Mankind Pharma's ANDA220513 for Thiamine Hydrochloride Receives AP Status

Mankind Pharma's application ANDA220513 for Thiamine Hydrochloride has received an Approval Pending (AP) status.

StrategyAugust 5, 2026

Mankind Pharma's Rosuvastatin Calcium ANDA206603 Receives AP Status

Mankind Pharma's ANDA for Rosuvastatin Calcium has been granted Abbreviated Approval (AP) status by the FDA.

RegulatoryAugust 5, 2026

FDA grants AP status for Atropine Sulfate ANDA218148 by Mankind Pharma

The FDA has granted approval status (AP) for the Abbreviated New Drug Application (ANDA) 218148 for Atropine Sulfate submitted by Mankind Pharma.

RegulatoryAugust 1, 2026

FDA Accepts Sugammadex Sodium Application from Mankind Pharma

The FDA has accepted the application for Sugammadex Sodium submitted by Mankind Pharma.

RegulatoryJuly 27, 2026

FDA Approves Brimonidine Tartrate Application ANDA220398 by Mankind Pharma

The FDA has approved the application ANDA220398 for Brimonidine Tartrate submitted by Mankind Pharma.

RegulatoryJuly 20, 2026

FDA Submission for Sitagliptin and Metformin Hydrochloride by Mankind Pharma

Mankind Pharma has submitted an original application (ANDA218405) for Sitagliptin and Metformin Hydrochloride.

RegulatoryJuly 13, 2026

FDA Grants AP Status for Atropine Sulfate ANDA218148 by Mankind Pharma

The FDA has granted approval status (AP) for the Abbreviated New Drug Application (ANDA218148) for Atropine Sulfate submitted by Mankind Pharma.

RegulatoryJuly 10, 2026

FDA Approval Application for Rivaroxaban by Mankind Pharma

Mankind Pharma has submitted an application for Rivaroxaban under ANDA220874, currently under standard review.

RegulatoryJuly 4, 2026

FDA Grants Approval for Brimonidine Tartrate ANDA220398 by Mankind Pharma

The FDA has granted approval for the ANDA of Brimonidine Tartrate submitted by Mankind Pharma.

RegulatoryJune 19, 2026

FDA Grants AP Status for Divalproex Sodium ANDA217358 by Mankind Pharma

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Divalproex Sodium submitted by Mankind Pharma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(9)

RegulatoryAugust 6, 2026

Mankind Pharma's ANDA220513 for Thiamine Hydrochloride Receives AP Status

Mankind Pharma's application ANDA220513 for Thiamine Hydrochloride has received an Approval Pending (AP) status.

RegulatoryAugust 5, 2026

FDA grants AP status for Atropine Sulfate ANDA218148 by Mankind Pharma

The FDA has granted approval status (AP) for the Abbreviated New Drug Application (ANDA) 218148 for Atropine Sulfate submitted by Mankind Pharma.

RegulatoryAugust 1, 2026

FDA Accepts Sugammadex Sodium Application from Mankind Pharma

The FDA has accepted the application for Sugammadex Sodium submitted by Mankind Pharma.

RegulatoryJuly 27, 2026

FDA Approves Brimonidine Tartrate Application ANDA220398 by Mankind Pharma

The FDA has approved the application ANDA220398 for Brimonidine Tartrate submitted by Mankind Pharma.

RegulatoryJuly 20, 2026

FDA Submission for Sitagliptin and Metformin Hydrochloride by Mankind Pharma

Mankind Pharma has submitted an original application (ANDA218405) for Sitagliptin and Metformin Hydrochloride.

RegulatoryJuly 13, 2026

FDA Grants AP Status for Atropine Sulfate ANDA218148 by Mankind Pharma

The FDA has granted approval status (AP) for the Abbreviated New Drug Application (ANDA218148) for Atropine Sulfate submitted by Mankind Pharma.

RegulatoryJuly 10, 2026

FDA Approval Application for Rivaroxaban by Mankind Pharma

Mankind Pharma has submitted an application for Rivaroxaban under ANDA220874, currently under standard review.

RegulatoryJuly 4, 2026

FDA Grants Approval for Brimonidine Tartrate ANDA220398 by Mankind Pharma

The FDA has granted approval for the ANDA of Brimonidine Tartrate submitted by Mankind Pharma.

RegulatoryJune 19, 2026

FDA Grants AP Status for Divalproex Sodium ANDA217358 by Mankind Pharma

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Divalproex Sodium submitted by Mankind Pharma.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

Atropine Sulfate →
Brimonidine Tartrate →
Divalproex Sodium →
FDA →
Mankind →
Rivaroxaban →
Rosuvastatin →
Sitagliptin →

Therapeutic areas

Anesthesia →
Anticholinergic →
Anticoagulant →
Antiepileptic →
Cardiovascular →
Cardiovascular · Anticholinergic →
Diabetes →
Diabetes · DPP-4 Inhibitor and Biguanide →
DPP-4 Inhibitor and Biguanide →
Glaucoma →
Neurology →
Neurology · Antiepileptic →
Neuromuscular Blockade →
Nutritional Deficiency →
Ophthalmology →
Ophthalmology · Glaucoma →
Statin →
Vitamin B1 →

Indications

Diabetes →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.